A new model of reverse cholesterol transport: EnTICEing strategies to stimulate intestinal cholesterol excretion

Trends in Pharmacological Sciences

Volumn 36, Issue 7, 2015, Pages 440-451

  Temel, Ryan E ^a   Brown, J Mark ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

bile; cholesterol; lipoprotein; reverse cholesterol transport; transintestinal cholesterol excretion

Indexed keywords

CHOLESTEROL; EZETIMIBE; HEPATIC FLAVIN MONOOXYGENASE 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER X RECEPTOR; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

ATHEROSCLEROSIS; BILE FLOW; CHOLESTEROL TRANSPORT; HUMAN; INHIBITION KINETICS; INTESTINAL EXCRETION; LIPID ABSORPTION; LIPID HOMEOSTASIS; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; LIVER; NONHUMAN; PRIORITY JOURNAL; REVERSE CHOLESTEROL TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; TRANSINTESTINAL CHOLESTEROL EXCRETION; BILE; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASE; CHEMISTRY; FECES; HEPATOBILIARY SYSTEM; INTESTINE; METABOLISM; SECRETION (PROCESS); TRANSPORT AT THE CELLULAR LEVEL;

BILE; BILIARY TRACT; BIOLOGICAL TRANSPORT; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; FECES; HUMANS; INTESTINES; LIVER; MODELS, BIOLOGICAL;

EID: 84933183026     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.04.002     Document Type: Review

References (130)

1. A.S. Go Executive summary: heart disease and stroke statistics - 2013 update: a report from the American Heart Association Circulation 127 2013 143 152
2. D.J. Rader, and A.R. Tall The not-so-simply HDL story: is it time to revise the HDL cholesterol hypothesis? Nat. Med. 18 2012 1344 1346
3. W.E. Boden Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N. Engl. J. Med. 365 2011 2255 2267
4. G.G. Schwartz Effect of dalcetrapib in patients with a recent acute coronary syndrome N. Engl. J. Med. 367 2012 2089 2099
5. B.F. Voight Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study Lancet 380 2012 572 580
6. J.M. Dietschy, and S.D. Turley Control of cholesterol turnover in the mouse J. Biol. Chem. 277 2002 3801 3804
7. D.J. Rader The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis J. Lipid Res. 50 Suppl. 2009 S189 S194
8. R.S. Rosenson Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport Circulation 125 2012 1905 1919
9. R.E. Temel Biliary sterol secretion is not required for macrophage reverse cholesterol transport Cell Metab. 12 2010 96 102
10. R.E. Temel, and J.M. Brown Biliary and nonbiliary contributions to reverse cholesterol transport Curr. Opin. Lipidol. 23 2012 85 90
11. J.K. Kruit Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice Gastroenterology 128 2005 147 156
12. A.E. Van der Velde Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice Gastroenterology 133 2007 967 975
13. J.M. Brown Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss J. Biol. Chem. 283 2008 10522 10534
14. J.N. van der Veen Activation of liver X receptor stimulates trans-intestinal excretion of plasma cholesterol J. Biol. Chem. 284 2009 19211 19219
15. C.L. Vrins PPARδ activation leads to increased trans intestinal cholesterol efflux J. Lipid Res. 50 2009 2046 2054
16. A.E. van der Velde Regulation of direct transintestinal cholesterol excretion in mice Am. J. Physiol. Gastrointest. Liver Physiol. 295 2008 G203 G208
17. L. Jakulj Ezetimibe stimulates faecal neutral sterol excretion depending on abcg8 function in mice FEBS Lett. 584 2010 3625 3628
18. C. Le May Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1 Arterioscler. Thromb. Vasc. Biol. 33 2013 1484 1493
19. L. Yu Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion Proc. Natl. Acad. Sci. U.S.A. 99 2002 16237 16242
20. G.A. Graf ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion J. Biol. Chem. 278 2003 48275 48282
21. H. Wiersma Scavenger receptor class B type I mediates biliary cholesterol secretion independent of ATP-binding cassette transporter g5/g8 in mice Hepatology 50 2009 1263 1272
22. R.E. Temel Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentrations and is a target of ezetimibe J. Clin. Invest. 117 2007 1968 1978
23. A. Groen Abcg5/8 independent biliary cholesterol excretion in Atp8b1-deficient mice Gastroenterology 134 2008 2091 2100
24. M.H. Sieber, and C.S. Thummel Coordination of triacylglycerol and cholesterol homeostasis by DHR96 and the Drosophila LipA homolog magro Cell Metab. 15 2012 122 127
25. P.J. Babin Both apolipoprotein E and A-I genes are present in a nonmammalian vertebrate and are highly expressed during embryonic development Proc. Natl. Acad. Sci. U.S.A. 94 1997 8622 8627
26. L. Wang Efficient delivery of miR-122 to regulate cholesterol metabolism using a non-covalent peptide-based strategy Mol. Med. Rep. 8 2013 1472 1478
27. R.E. Temel, and J.M. Brown A new framework for reverse cholesterol transport: non-biliary contributions to reverse cholesterol transport World J. Gastroenterol. 16 2010 5946 5952
28. U.J. Tietge, and A.K. Groen Role of TICE? Advancing the concept of transintestinal cholesterol excretion Arterioscler. Thromb. Vasc. Biol. 33 2013 1452 1453
29. A.E. Van der Velde Transintestinal cholesterol efflux Curr. Opin. Lipidol. 21 2010 167 171
30. J.K. Kruit Emerging roles of the intestine in control of cholesterol metabolism World J. Gastroenterol. 12 2006 6429 6439
31. G. Brufau Reverse cholesterol transport revisited: contribution of biliary versus intestinal cholesterol excretion Arterioscler. Thromb. Vasc. Biol. 31 2011 1726 1733
32. L. Jakulj Intestinal cholesterol secretion: future clinical implications Neth. J. Med. 71 2013 459 465
33. S.H. Cheng, and M.M. Stanley Secretion of cholesterol by intestinal mucosa in patients with complete common bile duct obstruction Proc. Soc. Exp. Biol. Med. 101 1959 223 225
34. M. Stanley Serum cholesterol esters and intestinal cholesterol secretion and absorption in obstructive jaundice due to cancer N. Engl. J. Med. 261 1959 368 373
35. W.J. Simmonds Absorption of cholesterol from a micellular solution: intestinal perfusion studies in man J. Clin. Invest. 46 1967 874 890
36. R.J. Deckelbaum Failure of complete bile diversion and oral bile acid therapy in the treatment of homozygous familial hypercholesterolemia N. Engl. J. Med. 296 1977 465 470
37. L. Hellman Isotopic studies of plasma cholesterol of endogenous and exogenous origins J. Clin. Invest. 34 1955 48 60
38. R. Rosenfeld, and L. Hellman The relation of plasma and biliary cholesterol to bile acid synthesis in man J. Clin. Invest. 38 1959 1334 1338
39. W.M. Sperry Lipid excretion IV. A study of the relationship of the bile to the fecal lipids with special reference to certain problems of sterol metabolism J. Biol. Chem. 71 1927 351 378
40. D. Pertsemlidis Regulation of cholesterol metabolism in the dog I. Effects of complete bile diversion and of cholesterol feeding on absorption, synthesis, accumulation, and excretion rates measured during life J. Clin. Invest. 52 1973 2353 2367
41. J.M. Dietschy The role of bile salts in controlling the rate of intestinal cholesterogenesis J. Clin. Invest. 47 1968 286 300
42. J.M. Dietschy, and M.D. Siperstein Cholesterol synthesis by the gastrointestinal tract: localization and mechanisms of control J. Clin. Invest. 44 1965 1311 1327
43. R.H. Bandsma Contribution of newly synthesized cholesterol to rat plasma and bile determined by mass isotopomer distribution analysis: bile-salt flux promotes secretion of newly synthesized cholesterol into bile Biochem. J. 329 1998 699 703
44. P.J. Voshol Reduced plasma cholesterol and increased fecal sterol loss in multidrug resistance gene 2 P-glycoprotein-deficient mice Gastroenterology 114 1998 1024 1034
45. J. Wang Relative roles of ABCG5/ABCG8 in liver and intestine J. Lipid Res. 56 2015 319 330
46. J.A. Glomset The plasma lecithin:cholesterol acyltransferase reaction J. Lipid Res. 9 1968 155 167
47. J.A. Glomset, and K.R. Norum The metabolic role of lecithin: cholesterol acyltransferase: perspectives from pathology Adv. Lipid Res. 11 1973 1 65
48. M.C. Phillips Molecular mechanisms of cellular cholesterol efflux J. Biol. Chem. 289 2014 24020 24029
49. G.H. Rothblatt, and M.C. Phillips High-density lipoprotein heterogeneity and function in reverse cholesterol transport Curr. Opin. Lipidol. 21 2010 229 238
50. J.M. Dietschy Role of the liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans J. Lipid Res. 34 1993 1637 1659
51. S. Acton Identification of scavenger receptor SR-BI as a high density lipoprotein receptor Science 271 1996 518 520
52. M. Krieger Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI Annu. Rev. Biochem. 68 1999 523 558
53. Y. Osono Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma Proc. Natl. Acad. Sci. U.S.A. 93 1996 4114 4119
54. C.D. Jolley Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-I concentration J. Lipid Res. 39 1998 2142 2149
55. A.K. Groen Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL J. Clin. Invest. 108 2001 843 850
56. C. Xie ABCA1 plays no role in centripetal movement of cholesterol from peripheral tissues to the liver and intestine in the mouse J. Lipid Res. 50 2009 1316 1329
57. M. Hellerstein, and S. Turner Reverse cholesterol transport fluxes Curr. Opin. Lipidol. 25 2014 40 47
58. F. Briand The use of dyslipidemic hamsters to evaluate drug-induced alterations in reverse cholesterol transport Curr. Opin. Investig. Drugs 11 2010 289 297
59. J. Castro-Perez Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters J. Lipid Res. 52 2011 1965 1973
60. P.J. Barter Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis Arterioscler. Thromb. Vasc. Biol. 23 2003 160 167
61. J.M. Timmins Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I J. Clin. Invest. 115 2005 1333 1342
62. L. Brunham Intestinal ABCA1 directly contributes to HDL biogenesis in vivo J. Clin. Invest. 116 2006 1052 1062
63. S. Kunnen, and M. Van Eck Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis J. Lipid Res. 53 2012 1783 1799
64. A. Yazdanyar Role of phospholipid transfer protein in high-density lipoprotein-mediated reverse cholesterol transport Curr. Atheroscler. Rep. 13 2011 242 248
65. V.I. Zannis HDL biogenesis, remodeling, and catabolism Handb. Exp. Pharmacol. 224 2015 53 111
66. A. Mulya Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL J. Lipid Res. 49 2008 2390 2401
67. A. Ji Impact of phospholipid transfer protein on nascent high-density lipoprotein formation and remodeling Arterioscler. Thromb. Vasc. Biol. 34 2014 1910 1916
68. J.Y. Lee Prebeta high density lipoprotein has two metabolic fates in human apolipoprotein A-I transgenic mice J. Lipid Res. 45 2004 716 728
69. L.O. Martinez Ectopic β-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis Nature 421 2003 75 79
70. A.C. Fabre P2Y13 receptor is critical for reverse cholesterol transport Hepatology 52 2010 1477 1483
71. N. Serhan Chronic pharmacologic activation of P2Y13 receptor in mice decreases HDL-cholesterol by increasing hepatic HDL uptake and bile acid secretion Biochim. Biophys. Acta 1831 2013 719 725
72. S. Jacquet The nucleotide receptor P2Y13 is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis Cell. Mol. Life Sci. 62 2005 2508 2515
73. D.L. Silver High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B type I results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion J. Biol. Chem. 276 2001 25287 25293
74. P.V. Burgos Cholesterol depletion induces PKA-mediated basolateral-to-apical transcytosis of the scavenger receptor class B type I in MDCK cells Proc. Natl. Acad. Sci. U.S.A. 101 2004 3845 3850
75. C.J. Harder SR-BI undergoes cholesterol-stimulated transcytosis to the bile canaliculus in polarized WIF-B cells J. Biol. Chem. 282 2007 1445 1455
76. D. Wustner Different transport routes for high density lipoprotein and its associated free sterol in polarized hepatic cells J. Lipid Res. 45 2004 427 437
77. A. Dikkers Scavenger receptor BI and ABCG5/G8 differentially impact biliary sterol secretion and reverse cholesterol transport in mice Hepatology 58 2013 293 303
78. S. Marshall Acute sterol o-acyltransferase 2 (SOAT2) knockdown rapidly mobilizes hepatic cholesterol for fecal excretion PLoS ONE 9 2014 e98953
79. K. Bura Intestinal SR-BI does not impact cholesterol absorption or transintestinal cholesterol efflux in mice J. Lipid Res. 54 2013 1567 1577
80. G. Brufau A reappraisal of the mechanism by which plant sterols promote neutral sterol loss in mice PLoS ONE 6 2011 e21576
81. S.W. Altmann Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption Science 303 2004 1201 1204
82. E. Sehayek, and S.L. Hazen Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages Arterioscler. Thromb. Vasc. Biol. 28 2008 1296 1297
83. A.S. Plump Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse Proc. Natl. Acad. Sci. U.S.A. 91 1994 9607 9611
84. C. Paszty Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice J. Clin. Invest. 94 1994 899 903
85. R.P. Choudhury High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation Arterioscler. Thromb. Vasc. Biol. 24 2004 1904 1909
86. P. Benoit Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models Circulation 99 1999 105 110
87. L.M. Belalcazar Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia Circulation 107 2003 2726 2732
88. E. Van Craeyveld Regression and stabilization of advanced murine atherosclerosis lesions: a comparison of LDL lowering and HDL raising gene transfer strategies J. Mol. Med. 89 2011 555 567
89. A. Miyazaki Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits Arterioscler. Thromb. Vasc. Biol. 15 1995 1882 1888
90. R.K. Tangirala Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice Circulation 100 1999 1816 1822
91. P.K. Shah High-dose recombinant apolipoprotein A-I (Milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Potential implications for acute plaque stabilization Circulation 103 2001 3047 3050
92. J.J. Badimon Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit J. Clin. Invest. 85 1990 1234 1241
93. J.X. Rong Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content Circulation 104 2001 2447 2452
94. J.E. Feig HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells Proc. Natl. Acad. Sci. U.S.A. 108 2011 7166 7171
95. M. Navab HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms Nat. Rev. Cardiol. 8 2011 222 232
96. A.R. Tall Cholesterol efflux: a novel regulator of myelopoiesis and atherogenesis Arterioscler. Thromb. Vasc. Biol. 32 2012 2547 2552
97. A.S. Shah Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond J. Lipid Res. 54 2013 2575 2585
98. K.C. Vickers, and A.T. Remaley HDL and cholesterol: life after the divorce? J. Lipid Res. 55 2014 4 12
99. X. Bi Liver ABCA1 deletion in LDLrKO mice does not impair macrophage reverse cholesterol transport or exacerbate atherogenesis Arterioscler. Thromb. Vasc. Biol. 33 2014 2288 2296
100. T. Plosch Increased hepatobiliary and fecal cholesterol excretion upon activation of the liver X receptor is independent of ABCA1 J. Biol. Chem. 277 2002 33870 33877
101. H. Tanigawa Lecithin:cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo Circulation 120 2009 160 169
102. D.M. Small Role of ABC transporters in secretion of cholesterol from liver into bile Proc. Natl. Acad. Sci. U.S.A. 100 2003 4 6
103. M.C. Carey, and D.M. Small The physical chemistry of cholesterol solubility in bile. Relationship to gallstone formation and dissolution in man J. Clin. Invest. 61 1978 998 1026
104. J.E. Wu Hepatic ABCG5 and ABCG8 overexpression increases hepatobiliary sterol transport but does not alter aortic atherosclerosis in transgenic mice J. Biol. Chem. 279 2004 22913 22925
105. F. Basso Hepatic ABCG5/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited J. Lipid Res. 48 2007 114 126
106. C.L. Vrins Trans-intestinal cholesterol efflux is not mediated through high density lipoprotein J. Lipid Res. 53 2012 2017 2023
107. S. Marshall Reduction of VLDL secretion decreases cholesterol excretion in Niemann-Pick C1-like 1 hepatic transgenic mice PLoS ONE 9 2014 e84418
108. A. Dikkers Differential impact of hepatic deficiency and total body inhibition of MTP on cholesterol metabolism and RCT in mice J. Lipid Res. 55 2014 816 825
109. Y. Zhang Hepatic overexpression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo J. Clin. Invest. 115 2005 2870 2874
110. N. Zelcer LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor Science 325 2009 100 104
111. J. Herz Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor EMBO J. 7 1988 4119 4127
112. P. Garcia-Miranda Rat small intestine expresses the reelin-Disabled-1 signaling pathway Exp. Physiol. 95 2010 498 507
113. N. Nijstad Biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice Gastroenterology 140 2011 1043 1051
114. J.R. Schultz Role of LXRs in control of lipogenesis Genes Dev. 14 2000 2832 2838
115. C. Hong The LXR-Idol axis differentially regulates plasma LDL levels in primates and mice Cell Metab. 20 2014 910 918
116. T. Yasuda Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo Arterioscler. Thromb. Vasc. Biol. 30 2010 781 786
117. G. Lo Sasso Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis Cell Metab. 12 2010 187 193
118. F. Briand Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal cholesterol reabsorption of HDL-derived cholesterol Clin. Transl. Sci. 2 2009 127 133
119. C. Maugeais rHDL administration increases reverse cholesterol transport in mice, but is not additive on top of ezetimibe or cholestyramine treatment Atherosclerosis 229 2013 94 101
120. H. Uto-Kondo Ezetimibe enhance macrophage reverse cholesterol transport in hamsters: contribution of hepatobiliary pathway Biochim. Biophys. Acta 1841 2014 1247 1255
121. M.H. Davidson Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans Atherosclerosis 230 2013 322 329
122. P. Xie Ezetimibe inhibits hepatic Niemann-Pick C1-like 1 to facilitate macrophage reverse cholesterol transport Arterioscler. Thromb. Vasc. Biol. 33 2013 920 925
123. M. Warrier The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance Cell Rep. 2015 10.1016/j.celrep.2014.12.036 Published online January 14, 2015
124. J.M. Brown, and S.L. Hazen Metaorganismal nutrient metabolism as a basis of cardiovascular disease Curr. Opin. Lipidol. 25 2014 48 53
125. Z. Wang Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease Nature 472 2011 57 63
126. R.A. Koeth Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis Nat. Med. 19 2013 576 585
127. W.H. Tang Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk N. Engl. J. Med. 368 2013 1575 1584
128. B.J. Bennett Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation Cell Metab. 17 2013 49 60
129. R.A. Koeth γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO Cell Metab. 20 2014 799 812
130. D.M. Shih Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis J. Lipid Res. 56 2015 22 37